JP2011520900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520900A5 JP2011520900A5 JP2011509662A JP2011509662A JP2011520900A5 JP 2011520900 A5 JP2011520900 A5 JP 2011520900A5 JP 2011509662 A JP2011509662 A JP 2011509662A JP 2011509662 A JP2011509662 A JP 2011509662A JP 2011520900 A5 JP2011520900 A5 JP 2011520900A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- epilepsy
- episode
- psd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 17
- 229940124597 therapeutic agent Drugs 0.000 claims 17
- 206010015037 epilepsy Diseases 0.000 claims 11
- 206010010904 Convulsion Diseases 0.000 claims 3
- 102100022264 Disks large homolog 4 Human genes 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 108700019745 Disks Large Homolog 4 Proteins 0.000 claims 2
- 102000000470 PDZ domains Human genes 0.000 claims 2
- 108050008994 PDZ domains Proteins 0.000 claims 2
- 229940123119 PSD-95 Inhibitor Drugs 0.000 claims 1
- 108010046423 Tat-NR2B9c Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- XWQVQFBTSBCKLI-FKXNDIMNSA-N dnc008987 Chemical group CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XWQVQFBTSBCKLI-FKXNDIMNSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000028329 epileptic seizure Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5410908P | 2008-05-16 | 2008-05-16 | |
| US61/054,109 | 2008-05-16 | ||
| PCT/US2009/043831 WO2009140416A2 (en) | 2008-05-16 | 2009-05-13 | Treatment for epilepsy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016109744A Division JP2016199553A (ja) | 2008-05-16 | 2016-06-01 | てんかんの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520900A JP2011520900A (ja) | 2011-07-21 |
| JP2011520900A5 true JP2011520900A5 (https=) | 2012-06-14 |
| JP6005357B2 JP6005357B2 (ja) | 2016-10-12 |
Family
ID=41319319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509662A Expired - Fee Related JP6005357B2 (ja) | 2008-05-16 | 2009-05-13 | てんかんの治療 |
| JP2016109744A Pending JP2016199553A (ja) | 2008-05-16 | 2016-06-01 | てんかんの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016109744A Pending JP2016199553A (ja) | 2008-05-16 | 2016-06-01 | てんかんの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9161965B2 (https=) |
| EP (1) | EP2307035B1 (https=) |
| JP (2) | JP6005357B2 (https=) |
| CN (1) | CN102088990A (https=) |
| AU (1) | AU2009246316B2 (https=) |
| CA (1) | CA2724483C (https=) |
| DK (1) | DK2307035T3 (https=) |
| ES (1) | ES2446306T3 (https=) |
| WO (1) | WO2009140416A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| DK2307035T3 (da) * | 2008-05-16 | 2014-01-20 | Nono Inc | Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi |
| CA2739416C (en) | 2008-09-03 | 2017-10-31 | Arbor Vita Corporation | Agents and methods for treatment of pain |
| US20140323924A1 (en) * | 2013-04-26 | 2014-10-30 | David J. Mishelevich | Targeted optogenetic neuromodulation for treatment of clinical conditions |
| WO2014121146A1 (en) | 2013-01-31 | 2014-08-07 | The Regents Of The University Of California | System and method for modeling brain dynamics in normal and diseased states |
| CN113546174A (zh) | 2015-02-25 | 2021-10-26 | 加利福尼亚大学董事会 | 用于治疗病症的5ht激动剂 |
| EP3383429B1 (en) | 2015-11-30 | 2020-10-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Nmdar antagonists for the treatment of tumor angiogenesis |
| KR102253900B1 (ko) * | 2016-04-27 | 2021-05-18 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 흥분성 신경독성 관련 손상 치료용 펩타이드 |
| EP3450446A1 (en) * | 2016-04-27 | 2019-03-06 | Biocells (Beijing) Biotech Co., Ltd. | Treatment method for excitatory neurotoxicity-related injury |
| US11241383B2 (en) | 2016-12-09 | 2022-02-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
| KR102403089B1 (ko) | 2017-07-05 | 2022-06-02 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도 |
| KR102545825B1 (ko) | 2017-09-30 | 2023-06-22 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물 |
| CA3085576A1 (en) | 2017-12-13 | 2019-06-20 | The Research Foundation For The State University Of New York | Peptides and other agents for treating pain and increasing pain sensitivity |
| EP3746138B1 (en) | 2018-02-02 | 2025-12-10 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
| US11911419B2 (en) * | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
| CA3153099A1 (en) * | 2019-09-17 | 2021-03-25 | Zogenix International Limited | Methods of treating epileptic patients with fenfluramine |
| CN110627877A (zh) * | 2019-09-25 | 2019-12-31 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
| CN111285923B (zh) * | 2020-03-05 | 2023-02-03 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060148711A1 (en) * | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US20050019841A1 (en) * | 1999-05-14 | 2005-01-27 | Arbor Vita Corporation | Modulation of signaling pathways |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US20090075377A1 (en) * | 2001-08-03 | 2009-03-19 | Arbor Vita Corporation | Molecular interactions in cells |
| US20050282743A1 (en) * | 2001-08-03 | 2005-12-22 | Arbor Vita Corporation | Molecular interactions in cells |
| EP1709084A4 (en) * | 2003-12-23 | 2008-05-28 | Nono Inc | POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS |
| WO2005097090A2 (en) * | 2004-04-05 | 2005-10-20 | Icos Corporation | AGENTS THAT DISRUPT PSD95 - nNOS INTERACTION, COMPOSITIONS CONTAINING THE SAME, AND THERAPEUTIC USES THEREOF |
| CA2613012A1 (en) * | 2005-06-23 | 2007-01-04 | Arbor Vita Corporation | Methods and compositions for modulating cox |
| US20070021501A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods of treating epileptogenesis |
| US8633160B2 (en) * | 2005-12-30 | 2014-01-21 | Nono Inc. | Small molecule inhibitors of PDZ interactions |
| KR101384572B1 (ko) * | 2005-12-30 | 2014-04-24 | 아버 비타 코포레이션 | Ｐｄｚ 상호작용의 소형 분자 억제제 |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| ES2446292T3 (es) * | 2007-03-02 | 2014-03-07 | Nono Inc. | Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| DK2307035T3 (da) * | 2008-05-16 | 2014-01-20 | Nono Inc | Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi |
| CA2739416C (en) * | 2008-09-03 | 2017-10-31 | Arbor Vita Corporation | Agents and methods for treatment of pain |
-
2009
- 2009-05-13 DK DK09747499.3T patent/DK2307035T3/da active
- 2009-05-13 JP JP2011509662A patent/JP6005357B2/ja not_active Expired - Fee Related
- 2009-05-13 WO PCT/US2009/043831 patent/WO2009140416A2/en not_active Ceased
- 2009-05-13 CA CA2724483A patent/CA2724483C/en active Active
- 2009-05-13 CN CN2009801274025A patent/CN102088990A/zh active Pending
- 2009-05-13 ES ES09747499.3T patent/ES2446306T3/es active Active
- 2009-05-13 AU AU2009246316A patent/AU2009246316B2/en not_active Ceased
- 2009-05-13 EP EP09747499.3A patent/EP2307035B1/en active Active
- 2009-05-14 US US12/466,208 patent/US9161965B2/en active Active
-
2016
- 2016-06-01 JP JP2016109744A patent/JP2016199553A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520900A5 (https=) | ||
| WO2008011174A3 (en) | Jak inhibitors for treatment of myeloproliferative disorders | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| TWI371276B (en) | Use of brimonidine for manufacture of a medicament for preventing or reducing severity of sensory hypersensitivity associated with migratine | |
| WO2007025613A3 (en) | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | |
| EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
| MX2009012163A (es) | Hetarilanilinas como moduladores para beta-amiloide. | |
| WO2009132656A3 (en) | Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin | |
| IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
| JP2007523178A5 (https=) | ||
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| MX2009012188A (es) | Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos. | |
| WO2009140416A3 (en) | Treatment for epilepsy | |
| MX2012003324A (es) | Compuesto de glicina. | |
| WO2008011083A3 (en) | Compounds for enhancing arginase activity and methods of use thereof | |
| JP2016501219A5 (https=) | ||
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| WO2015079010A3 (en) | Pharmaceutical composition comprising lacosamide and levetiracetam | |
| WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
| WO2011034775A3 (en) | Methods for treating brain tumors | |
| WO2008073466A3 (en) | Alpha b-crystallin as a therapy for inflammation | |
| TW201129361A (en) | Methods for treating pain | |
| WO2012138879A3 (en) | Peptides for the treatment of hearing | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. |